Introduction
Central retinal artery occlusion (CRAO) is an acute vascular event characterized by painless unilateral visual impairment. The incidence of CRAO is relatively low, approximately 1-15 people per 10 000 [1-3]. Clinically, CRAO presents with acute-onset and profound visual loss very often associated with a poor visual prognosis [2, 4] . CRAO is a serious ophthalmologic emergency that possibly with timely treatment can minimize the degree of visual compromise [5, 6] . A thromboembolic event of the central retinal artery is felt to be the primary cause in most cases of CRAO [1, 2] . Approximately 20% of patients with CRAO have concomitant carotid artery disease, which may present as transient monocular visual loss (amaurosis fugax) or transient hemispheric ischemic attack prior to the permanent loss of vision [5, 7] . In older individuals (more than 55 years of age), CRAO may be the result of giant cell arteritis (GCA) [8, 9] .
CRAO results in infarction of the inner retina leading to a quantifiable reduction in the thickness of the inner retinal layers [10] . Although spontaneous recovery is possible, it is uncommon and unpredictable [11] . In addition to visual compromise, a serious ocular complication of CRAO is iris neovascularization, which can ultimately lead to neovascular glaucoma in approximately 5% of cases [12] . Patients with CRAO are also at a high risk of heart disease and acute ischemic stroke [1, 13] . Individuals with visible retinal emboli (regardless of whether occlusion is present) have a 56% mortality rate over 9 years and those with CRAO carry a shorter life expectancy when compared with non-CRAO controls [14] .
Epidemiology
As mentioned above, the incidence of CRAO is low and there appears to be no age, sex, race, or ethnic bias [1, 11] . Typically, CRAO is unilateral but can occur in both eyes simultaneously in 1-2% of cases [1, 2] . atherosclerotic disease [1] [2] [3] . In particular, systemic diseases more commonly seen in patients with CRAO are as follows [1-9,11]:
(1) diabetes mellitus; (2) collagen vascular disease; (3) hyperuricemia; (4) blood dyscrasia (i.e. antiphospholipid syndrome, hemophilia, protein C deficiency, antithrombin III deficiency); (5) chronic smoking; (6) hyperlipidemia; (7) hypercoagulopathies; (8) cardiac valvular disease; (9) carotid artery disease; (10) atrial fibrillation; (11) systemic arterial hypertension.
Individuals with cardiovascular disease (valvular heart disease, endocarditis, aortic arch disease, and carotid artery disease) are at a higher risk for developing CRAO [6, 9, 11] . A recent study [11] evaluating 1379 patients with CRAO noted 9% of patients had atrial fibrillation, 18% had carotid artery disease, and 19% had an ischemic stroke. Other vasculitides that can cause CRAO aside from GCA include systemic lupus erythematous, polyarteritis nodosum, HenochSchö nlein purpura, Wegener's granulomatosis, and Kawasaki's disease [6, [15] [16] [17] [18] .
Clinical presentation
CRAO typically presents as sudden, painless, unilateral loss of vision. The visual loss is often severe (worse than 20/200) but patients seldom exhibit absence of light perception [19] [20] [21] . Some patients may experience amaurosis fugax prior to the visual loss, suggesting carotid artery disease or GCA [2, 5, 9] .
Occlusion of the central retinal artery leads to compromised blood supply to the retina, resulting in arterial attenuation and retinal opacification associated with a 'cherry red spot'. Sludging of red blood cells can be seen in the retinal arterial circulation, a process known as boxcarring. In some cases, there may be single or multiple emboli visible throughout the retinal arterioles [11, 19] , and occasionally there may be optic disc edema [9] . Retinal hemorrhages are seldom seen.
A prospective study [22] of 2000 normal eyes found 14.6% of eyes have a cilioretinal artery. Cilioretinal artery has a greater predilection for occlusion in the setting of CRAO because of its lower perfusion pressure compared with the central retinal artery [22] . Twenty-five percent of eyes with CRAO have a cilioretinal artery [23] .
CRAO has been subdivided into four clinical categories according to observable changes in the retina, optic disk, and retinal vessels (Table 1) [9, 20, 21, 23] .
Diagnostic evaluation
The fundus appearance of CRAO (see above) is often diagnostic of the disease and few ancillary tests are required to confirm the clinical findings. Intravenous fluorescein angiography (IVFA) and optical coherence tomography (OCT) can be useful as confirmatory tests in the setting of an uncertain diagnosis [2, 9, 10] . IVFA characteristically shows delayed or restricted retinal arteriole filling [24] , whereas OCT displays increased inner retinal layer thickness in the acute phase [10] . Additional clinical evaluation is directed toward determining the underlying cause of CRAO. The presence of systemic symptoms (such as headaches, scalp tenderness, and arthralgias), optic disc edema, and involvement of the posterior ciliary arteries as seen by IVFA should raise the concern for GCA, and an immediate erythrocyte sedimentation rate and C-reactive protein should be obtained [23, 25] .
A number of paraclinical tests may be necessary to determine the source of the embolus. Evaluation of the extracranial carotid system can be performed by ultrasonography, magnetic resonance angiography (MRA), or computed tomography angiography (CTA) [10] . An ECG can identify an underlying cardiac arrhythmia. Transesophageal echocardiography (TEE) is effective in detecting cardiac valvular and great vessel (aortic arch) disease [26] . Blood cultures and hypercoagulable tests may be warranted to evaluate for bacterial endocarditis and blood dyscrasias, respectively. CRAO is associated with an increased mortality rate; therefore, patients should undergo a complete medical evaluation in addition to aggressive modification of any and all cardiovascular risk factors [11] .
Acute treatment
Currently, there is no proven effective treatment for CRAO [2, 16, 19] . There are several important factors in 'Conservative' strategies to treat CRAO include ocular massage, physical exercise, reduction of intraocular pressure (IOP), and increasing the carbon dioxide concentration in the blood (Table 2) [1-3, 19, [28] [29] [30] . In theory, these treatments work by dislodging the embolus distally down the arterial system thereby minimizing the area of retinal ischemic damage. Other conservative treatment strategies such as hemodilution, hyperbaric oxygen treatment, and supine positioning presumably work by increasing the delivery of oxygen to the retina [3, 19, 28] . A recent Cochrane review [31] concluded that the currently available conservative treatments do not significantly alter the natural course of CRAO.
Thrombolytic therapy
Thrombolytic therapy involves the use of clot-dissolving medications to lyse thrombi in the arterial vasculature. Some common thrombolytic therapy agents include tissue plasminogen activator (t-PA), reteplase, tenecteplase, anistreplase, streptokinase, and urokinase. Clot lysis occurs because these agents convert plasminogen to plasmin, the active molecule for fibrin degradation (fibrinolysis). Thrombolytic therapy can be administered intravenously (i.v.) or intraarterially. The i.v. route is often preferred because it is quick and relatively easy to administer in a nontertiary setting. Although effective in initiating local clot lysis, i.v. thrombolytic therapy can result in widespread activation of plasminogen and a generalized hypocoagulable state [32 ,33-35] . In comparison, intraarterial thrombolytic therapy is a more targeted and relatively better tolerated method because it involves selective catheterization of the effected vessel allowing localized delivery of the thrombolytic agent.
The swift restoration of retinal blood flow is vital for the preservation of retina [36] . Thus, successful treatment of CRAO with thrombolytic therapy hinges on its ability to effectively restore near normal circulation as soon as possible [36, 37] . On the basis of the clinical trials of acute ischemic stroke, it would appear that thrombolytic therapy should be administered within 4.5 h of the onset of symptoms because the potential for neurological rescue declines beyond this time period [35] .
Thrombolytic therapy was first proven effective in the treatment of ischemic heart disease (IHD) [38] . The favorable results of thrombolytic therapy in the treatment of IHD led to its study in acute ischemic stroke [39] [40] [41] . On the basis of the results of the National Institutes of Neurological Disorders and Stroke (NINDS) trial [41] , t-PA is the only thrombolytic agent approved for treatment of acute ischemic stroke. Three hundred and three patients were treated with i.v. t-PA within 3 h of the onset of symptoms. Using a global test statistic to assess clinical outcome, patients treated with t-PA were at least 30% more likely to have minimal or no disability at 3 months compared with patients who received placebo. The promising results in IHD and acute ischemic stroke 212 Retinal, vitreous and macular disorders coupled with the theoretic similarities of the thromboembolic event within the retinal circulation led to the application of thrombolytic therapy for CRAO [34] .
Recent studies of thrombolytic therapy
Thrombolytic therapy has been suggested as a promising alternative therapy to conservative treatment for CRAO [11, [42] [43] [44] [45] [46] [47] . Thrombolytic therapy for CRAO can be delivered either i.v. or intraarterial. Despite numerous publications studying the effectiveness of both i.v. thrombolytic therapy and intraarterial thrombolytic therapy for CRAO [11, 37, [42] [43] [44] [45] [46] [47] , the benefits remain uncertain with no current consensus on its use [11, 34, 37] .
Intravenous thrombolytic therapy
Intravenous thrombolytic therapy has been used in the treatment of CRAO since the 1960s [48] . Although there have been a number of case reports and retrospective case series published [48] [49] [50] [51] [52] [53] [54] [55] [56] , there have been only two nonrandomized prospective studies on the treatment of CRAO with i.v. thrombolytic therapy. In the first study involving 12 patients with CRAO, Kattah et al. [36] observed visual improvement in 10 patients after i.v. thrombolytic therapy. Four patients had eight lines of visual improvement and six patients had two to four lines of visual improvement 3 days after thrombolysis (nine of these patients maintained their visual improvement 3 months after thrombolysis). The second study focused on examining whether the visual prognosis after i.v. thrombolytic therapy was related to the time of administration. A low dose (50 mg) of i.v. recombinant t-PA (rt-PA) and concomitant i.v. heparinization was given to 28 eyes with CRAO [32 ] . Seven of 17 eyes (41%) that received i.v. thrombolytic therapy within the first 6.5 h after onset of symptoms achieved a final visual acuity of 20/50 or better, compared with no eyes in the subgroup that was treated more than 6.5 h from the onset of their symptoms [32 ] .
Intraarterial thrombolytic therapy
Because of the potential systemic complications associated with i.v. thrombolytic therapy, some investigators have studied the use of intraarterial thrombolytic therapy for CRAO [11, 21, 57, 58] . In a recent nonrandomized, single-center study [59 ] , the visual outcome of 42 patients with CRAO who received 3 mg aliquots of intraarterial t-PA was compared with 21 patients who received conventional therapy. Seventy-six percent of patients in the intraarterial t-PA group experienced visual improvement of at least one line compared with only 33% of patients in the conventional therapy group. Furthermore, 33% of the patients who received intraarterial t-PA experienced three lines or more of visual improvement compared with only 4.8% of patients in the conventional therapy group. Although these results are promising, the small patient population and lack of randomization limit the recommendation strength of the study.
Arnold et al. [57] examined the efficacy of intraarterial thrombolytic therapy in 37 patients with CRAO. Intraarterial thrombolytic therapy was administered within 6 h of symptom onset in all patients, but only 22% demonstrated improved vision as compared with the conventional treatment group [57] . The study found that younger patients had an improved chance of achieving better visual recovery than their older counterparts [57] . Schumacher et al. [60] studied intraarterial thrombolytic therapy with urokinase and rt-TPA given within 6-8 h of symptom onset and found 26% of patients demonstrated significant improvement in visual acuity. The authors also found little effect on vision when thrombolytic therapy was administered 20 h or more after the onset of symptoms [60] .
Although no defined window of opportunity for using thrombolytic therapy in CRAO has been established, some experts maintain a goal of 3 h from the onset of symptoms [57] . In addition, CRAO has been equated to an anterior cerebral circulation stroke and, thus, should possibly follow similar guidelines recommended for the treatment of acute ischemic stroke [32 ,61] . Existing institutional treatment protocols for thrombolytic therapy in acute ischemic stroke, such as at the Duke University Medical Center, may offer an instructive framework upon which to devise an effective treatment algorithm for the diagnosis and treatment of CRAO (Table 3) [62] .
Complications and disadvantages of thrombolytic therapy
Although i.v. thrombolytic therapy administration is, from a logistical point of view, a relatively straightforward process, the administration of intraarterial thrombolytic therapy involves a multispecialty approach requiring careful inpatient monitoring of vital functions and coagulation factors during and after treatment [37] . Intraarterial thrombolytic therapy requires a trained interventional neuroradiology team, which may not be available in all hospitals. Even with the appropriate available infrastructure, it can be difficult to streamline patient care to administer thrombolytic therapy within the proposed therapeutic window period. In addition, many patients often fail to recognize or may present many hours after the onset of their symptoms precluding them from thrombolytic therapy.
Thrombolytic therapy may predispose patients to potentially fatal intracerebral hemorrhaging, adverse allergic reactions, or other systemic side effects [41] . In fact, agents with shorter half-lives, such as t-PA, are preferred as administering them locally can reduce the risk of adverse reactions when compared with other longer acting thrombolytic therapy agents [58] . The complication rate of i.v. thrombolytic therapy for CRAO is not known. Prior to administration, monitor BP every 15 min Following t-PA administration, assess neurologic status and monitor vital signs for 24 h as follows: every 15 min for 2 h; then every 30 min for 6 h; then every 1 h and obtain neurological examination every 2 h for the remaining 16 h of the 24-h period post-t-PA infusion Monitor PT, aPTT, and CBC as ordered Monitor BP (goal is less than 185 mmHgSBP and less than 110 mmHg DBP or within prescribed parameters), notify MD/neurologist if parameters are exceeded by patient Apply external pressure to any bleeding sites until bleeding ceases and notify MD/neurologist Do not administer anticoagulants (i.e. heparin and coumadin), heparinoids, low-molecular-weight heparins or antiplatelet agents [i.e. aspirin, plavix, and Aggrenox (Boehringer Ingelheim Pharma KG, Biberach, Germany)] for the first 24 h following t-PA infusion Avoid invasive procedures (i.e., Foley catheter insertion, nasogastric tube placement, arterial puncture, venipuncture, intramuscular injection, per rectal medications etc.) for the first 24 h after t-PA infusion unless emergent
In the largest case series of i.v. thrombolytic therapy for CRAO (23 patients), four developed cerebral hemorrhage and one developed cardiovascular shock [51] . There have been at least two other cases reported in the literature of fatal cerebral hemorrhage following i.v. thrombolytic therapy for CRAO [48, 55] .
In general, intraarterial thrombolytic therapy appears to be better tolerated than i.v. thrombolytic therapy. Suri et al. [11] conducted a meta-analysis of 1379 patients with CRAO and found intraarterial thrombolytic therapy was not associated with an increase in mortality rate or risk of intracranial hemorrhage. Another meta-analysis by Noble et al. [21] regarding intraarterial thrombolytic therapy found an overall complication rate of 4.5% (10/220), including one local hemorrhage, five transient ischemic attacks (TIAs), one hypertensive crisis, one intracerebral hemorrhage, and two completed ischemic strokes. Similarly, a meta-analysis by Biousse et al. [34] noted that intraarterial thrombolytic therapy yielded a complication rate of 10% (25/249), with 12 TIAs, six minor cerebral infarctions, two serious cerebral infarctions, two cerebral hemorrhages, and two groin hematomas. There are several absolute contraindications to the use of thrombolytic therapy in acute ischemic stroke [1-3,11,20,28-30,32 ]:
(1) chest pain, (2) recent head trauma or surgery, (3) gastrointestinal ulceration or hemorrhage within past 3 months or active peptic ulcer disease, (4) cerebrovascular ischemia or any history of intracranial bleeding within past 12 months, (5) bacterial endocarditis, (6) pregnancy or recent obstetric delivery (14 weeks or earlier: assess maternal vs. fetal risk), (7) severe hypertension (systolic blood pressure more than 160 mmHg/diastolic blood pressure more than 100 mmHg), (8) hypertensive retinopathy, (9) GCA, (10) proliferative diabetic retinopathy, (11) current anticoagulant use [international normalized ratio (INR) more than 2-3 has increased risk for bleeding events), (12) recent (within 3 months) hemorrhagic stroke or TIA, (13) suspected aortic dissection, (14) intramuscular injection within past week, (15) active internal bleeding, (16) intracranial neoplasm, (17) documented hypersensitivity.
Furthermore, the effects of thrombolytic therapy may be potentiated in individuals taking medications such as aspirin, anticoagulants, antiseizure medications (e.g. valproic acid and divalproex sodium), and cephalosporin antibiotics [2, [63] [64] [65] . Given its propensity for adverse reactions, careful screening of eligible patients is warranted prior to the administration of thrombolytic therapy.
Future prospects
Despite recent widespread enthusiasm surrounding the use of thrombolytic therapy in CRAO, the absence of randomized clinical trials calls into question the proven efficacy of such a treatment paradigm at this time [23] . Framme et al. [47] found no statistically significant visual improvement in CRAO patients treated with thrombolytic therapy when compared with those treated with other common treatments. Some experts have concluded that despite its efficacy in treating acute ischemic stroke, conflating the management of CRAO with that of acute ischemic stroke is erroneous [23, 66] . This notion is underscored by the finding that over 80% of emboli in CRAO consist of cholesterol or calcified material, which are not theoretically treatable with thrombolytic therapy [23] . It is also worth noting that the vast majority of studies examining thrombolytic therapy in CRAO have not only been retrospective and nonrandomized but have failed to account for the various classifications of CRAO [23] .
The absence of conclusive studies supporting thrombolytic therapy in CRAO is particularly important when one considers the potentially catastrophic neurological complications associated with thrombolytic therapy [11, 34, 37] . The multicenter study of the European Assessment Group for Lysis in the Eye (EAGLE) represents the first randomized, prospective clinical trial to compare conventional treatment with intraarterial thrombolytic therapy in patients with CRAO. Although the final results of this study have not yet been published, the authors are enthusiastic that their findings will 'enable ophthalmologists and neuroradiologists to improve the therapy of patients with acute CRAO' [67] . However, this enthusiasm has been dampened by the comments of some experts regarding the validity of the study describing its protocol as 'sketchy and vague' and noting that the study fails to prevent important selection biases [68] .
In the event that future randomized studies unambiguously and convincingly demonstrate the efficacy and safety of thrombolytic therapy in CRAO, ophthalmologists and healthcare providers should consider the following issues and potential hurdles to the successful implementation of thrombolytic therapy as a standardized treatment for CRAO:
(1) Development of an organizational infrastructure that facilitates the well tolerated administration of i.v. thrombolytic therapy, intraarterial thrombolytic therapy, or both in a timely manner. (2) A systematic institutional approach with the integral involvement of ophthalmologists, stroke specialists, emergency physicians, and neuroradiologists. (3) Development of a specific thrombolytic therapy protocol to maximize benefit and minimize complications. (4) A consensus on who will be responsible for the administration of i.v. thrombolytic therapy (e.g. emergency physician, ophthalmologist, neurologist, etc.). Currently, most hospitals allow emergency physicians to administer i.v. thrombolytic therapy for an acute ischemic stroke [69] [70] [71] , a situation that may not necessarily be appropriate for patients with CRAO. (5) The medicolegal ramifications of thrombolytic therapy associated with CRAO [69] . (6) Lack of public awareness of CRAO resulting in a delay in seeking medical care. To overcome this problem, it will require extensive public education and awareness programs. (7) The large financial cost of thrombolytic therapy [11] .
In a recent study involving 1379 CRAO patients, Suri et al. [11] showed the mean hospital cost of not receiving thrombolytic therapy was dramatically less than the hospital cost of thrombolytic therapy ($14 500 vs. 32 500-37 800, respectively).
Conclusion
CRAO is a clinical emergency leading to abrupt and, in most cases, irreversible loss of vision. Although no consensus exists on a standardized treatment strategy, emerging evidence suggests that thrombolytic therapy may be an effective strategy for CRAO if administered within what appears to be a narrow window of time. However, further studies are needed to better analyze the benefit, risk, and cost of thrombolytic therapy in CRAO. At this time, it is the authors' opinion that thrombolytic therapy in CRAO is a cutting edge therapy that may prove to be standard of care therapy; but it remains to be seen whether it will be a practical therapy outside of the controlled environment of a clinical trial.
